glp 1 hip pain 4Moving Biotech shares innovative trial plans for GLP-1 osteoarthritis drug How a discovery in joint

T., Go, V

Results After propensity score matching, 7,827 participants were analyzed

Strategic Expansion Creates Future Optionality In addition to advancing its core GLP-1 metabolic disease platform, SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio

The day of the assay, cells were washed in KRB-HEPES buffer (KRBH buffer: 135 mM NaCl, 3.6 mM KCl, 0.5 mM NaH 2 PO 4 , 0.5 mM MgSO 4 , 1.5 mM CaCl 2 , 2 mM NaHCO 3 , and 10 mM HEPES, pH 7.4) and 0.1% BSA, preincubated at 37 C for 30 min in KRBH-1% BSA and washed again in KRBH-0.1% BSA